Le panel citoyen « Mieux vivre à Stalingrad », L’expérience menée à Paris

« DÉMOCRATIE PARTICIPATIVE ET RÉDUCTION DES RISQUES » COMMENT ASSOCIER LA POPULATION LOCALE À LA RÉSOLUTION DES PROBLÈMES D’UN QUARTIER ? 56e RENCONTRE DU CRIPS ÎLE-DE-FRANCE – 14 OCTOBRE 2004 LETTRE D’INFORMATION – N°73   DOUBLE INTERVENTION : BERNARD JOMIER ET ANNE COPPEL   BERNARD JOMIER, ADJOINT AU MAIRE, CHARGÉ DE LA SANTÉ, MAIRIE DU […]

The institutional and historical context of introduction of opioid replacement therapy in France, and the situation of France in this field compared to other comparable countries

Summary

The main characteristics of opioid replacement therapy in France are: 1) the large number of patients, almost 100,000 ; 2) the use of high-dose buprenorphine ; 3) about eight out of ten patients are treated by GPs. The development of opioid replacement therapy is both very recent (1995, Marketing Authorisation) and very rapid. Although cases of misuse have been observed (injection, resale on the black market), a national evaluation showed that development of these treat- ments has been accompanied by an improvement of health and social integration (80 % reduction of fatal overdoses, reduction of syringe sharing, 67% reduction of arrests for heroin use between 1994 and 1999 – see INVS, 2001). These good results are due to a large access to care and Good Clinical Practice by a majority of practitioners. On the basis of follow- up studies, about two-thirds of patients obtain a benefit from these treatments. An improvement of current results would require adaptation of the management of poorly stabilized patients, with a broader access to care, including easier access to methadone. Erratic practices must be controlled by publi- shing good clinical practice guidelines, training of practitioners and improvement of the quality of the relationship with patients.

Dans quel contexte historique et institutionnel ont été mis en place les traitements de substitution en France et comment notre pays se situe-t-il par rapport aux pays comparables ?

Conférence de consensus sur les traitements de substitution Revue Alcoologie addictologie Décembre 2004, Tome 26, supplément au n°4, pp. 17-26   En 1989, la DGS a commandé une étude sur le devenir des toxicomanes. Comment évaluer la mortalité des toxicomanes puisqu’il n’y a pas d’étude ou de recherche française? L’épidémiologue sollicité réunit les principales études […]